CRIS Curis, Inc.

1.70
-0.01  -1%
Previous Close 1.71
Open 1.74
Price To book 11.48
Market Cap 244.41M
Shares 143,772,000
Volume 465,169
Short Ratio 3.97
Av. Daily Volume 579,295

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved January 30, 2012.
Vismodegib
Basal Cell Carcinoma
Phase 2 initial data due 1H 2017.
CUDC-907
Diffuse-large B-cell lymphoma (DLBCL)

Latest News

  1. Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting
  2. ETFs with exposure to Curis, Inc. : May 22, 2017
  3. Edited Transcript of CRIS earnings conference call or presentation 4-May-17 12:30pm GMT
  4. Top 3 Healthcare Penny Stocks for 2017
  5. Curis, Inc. :CRIS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
  6. Curis reports 1Q loss
  7. Investor Network: Curis, Inc. to Host Earnings Call
  8. Curis Reports First Quarter 2017 Financial Results
  9. Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017
  10. Curis, Inc. – Value Analysis (NASDAQ:CRIS) : April 25, 2017
  11. Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : April 24, 2017
  12. Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  13. Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting
  14. ETFs with exposure to Curis, Inc. : March 27, 2017
  15. Curis, Inc. :CRIS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  16. Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference
  17. Curis, Inc. :CRIS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  18. Markets Rally Late to Close in the Green: Today's Research Reports on Stocks to Watch Curis and Staples